Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Takeda, Millennium to participate in anti-cancer agent Phase III trial
Takeda Bio Development Center (Takeda Bio), a wholly owned subsidiary of Takeda, has initiated the Japanese portion of the trial and will lead AMG 479’s development in Japan.
Takeda Bio Development Center (Takeda Bio), a wholly owned subsidiary of Takeda, has initiated the Japanese portion of the trial and will lead AMG 479’s development in Japan.
In December 1994, the International Society for Cellular Therapy (ISCT) and the American Society for Blood and Marrow Transplantation (ASBMT) merged their standards into a single document covering
The acquisition prodives RXi Pharma with to access NeuVax, a peptide-based immunotherapy for low-to-intermediate HER2+ breast cancer, patients who are not eligible for Herceptin RXi has targeted NeuVax
Under the agreement, Imperial College will take up the responsibility for VAL101’s late preclinical development. The aim is to provide validation for the GeneICE clinical applications and validation
RayVa is designed to be applied as a cream to fingers or toes, delivering alprostadil directly to the area of need, in order to stimulate blood flow. Apricus
As per the terms of the agreement, both the parties will together organize preclinical research. The collaboration will combine Amunix’s protein half-life engineering expertise, based on its proprietary
Debiopharm said Debio 1142 project aims at developing inhibitors targeting a key oncology pathway, which plays essential roles in various solid tumours, including resistance to chemotherapy. Aurigene CEO
Resminostat is currently being evaluated in Phase II trials by 4SC in hepatocellular carcinoma (HCC), Hodgkin lymphoma (HL) and colorectal cancer in KRAS-mutant patients (CRC). As per the
Dr Reddy’s will market the product under store brand labels in the US market. OTC fexofenadine HCl tablets are the generic version of Sanofi-aventis’ Allegra tablets, which received
Tripos provides scientific solutions enabling life science researchers to improve the efficiency of molecular discovery. Certara focuses on reducing the barriers between the phases of research to speed